DE69409237T2 - Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten - Google Patents

Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Info

Publication number
DE69409237T2
DE69409237T2 DE69409237T DE69409237T DE69409237T2 DE 69409237 T2 DE69409237 T2 DE 69409237T2 DE 69409237 T DE69409237 T DE 69409237T DE 69409237 T DE69409237 T DE 69409237T DE 69409237 T2 DE69409237 T2 DE 69409237T2
Authority
DE
Germany
Prior art keywords
peptide
protein
antibody
pharmaceutical compositions
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69409237T
Other languages
English (en)
Other versions
DE69409237D1 (de
Inventor
Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of DE69409237D1 publication Critical patent/DE69409237D1/de
Application granted granted Critical
Publication of DE69409237T2 publication Critical patent/DE69409237T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule
DE69409237T 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten Expired - Fee Related DE69409237T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions
PCT/GB1994/001201 WO1994028879A1 (en) 1993-06-03 1994-06-02 Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads

Publications (2)

Publication Number Publication Date
DE69409237D1 DE69409237D1 (de) 1998-04-30
DE69409237T2 true DE69409237T2 (de) 1998-10-29

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69409237T Expired - Fee Related DE69409237T2 (de) 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Country Status (9)

Country Link
EP (1) EP0707473B1 (de)
AT (1) ATE164311T1 (de)
AU (1) AU6804394A (de)
DE (1) DE69409237T2 (de)
DK (1) DK0707473T3 (de)
ES (1) ES2117272T3 (de)
GB (1) GB9311454D0 (de)
WO (1) WO1994028879A1 (de)
ZA (1) ZA943920B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0991403T3 (da) 1997-01-30 2003-07-28 Chiron Corp Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
IT1291559B1 (it) 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
CA2420621C (en) 2000-09-28 2011-05-24 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
EP2267032A3 (de) 2002-11-08 2011-11-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
EP1888640B1 (de) 2005-05-18 2012-03-14 Ablynx N.V. Verbesserte nanokörper gegen tumornekrosefaktor-alpha
PL3415535T3 (pl) 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
NZ242220A (en) * 1991-04-02 1994-04-27 Biotech Australia Pty Ltd Complex for oral delivery of a substance to the circulatory or lymphatic drainage system comprising microparticle coupled to at least one carrier, the substance being encapsulated by the microparticle

Also Published As

Publication number Publication date
DE69409237D1 (de) 1998-04-30
EP0707473B1 (de) 1998-03-25
ZA943920B (en) 1995-12-04
ES2117272T3 (es) 1998-08-01
WO1994028879A1 (en) 1994-12-22
GB9311454D0 (en) 1993-07-21
DK0707473T3 (da) 1999-01-04
ATE164311T1 (de) 1998-04-15
EP0707473A1 (de) 1996-04-24
AU6804394A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
DE69230670D1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
DE69431060T2 (de) Klonierte glutaminsäure-decarboxylase
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
DE69428040D1 (de) Orale darreichungsform
DE69409237D1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DK235687D0 (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
FR2577557B1 (fr) Peptides et derives peptidiques, leur preparation, leur utilisation en therapeutique et compositions pharmaceutiques les contenant
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
FI893681A (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
KR900701300A (ko) 생물학적 활성 펩티드 및 특정음이온을 갖는 조성물 및 이것을 사용하는 방법
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
DE69002881D1 (de) Peptide und deren Benutzung.
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
DE69029259D1 (de) Polypeptid, dessen herstellung, und dieses polypeptid enthaltende pharmazeutische verbindungen und kosmetika
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
IT8947833A0 (it) Peptidi somatostatinici, procedimento per la loro produzione, preparati farmaceutici che li contengono e loro uso come medicamenti
ATE4196T1 (de) Ovulation stimulierende peptide und deren pharmazeutische zusammensetzungen.
ATE6639T1 (de) Ein gereinigtes polypeptid, ein verfahren zu dessen herstellung, dessen anwendung und das enthaltende pharmazeutische praeparat.
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.
IT8621261A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee